MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC

Authors :: Matthew Squires
Monica Giovannini
Todd M. Bauer
Ji-Youn Han
Arndt Vogel
Angelo Delmonte
Maja J.A. de Jonge
Martin Schuler
Maya Gottfried
Mira Wollner
Dae Ho Lee
Wan-Teck Lim
Dong Wan Kim
Mikhail Akimov
Robin M.J.M. van Geel
Analia Azaro
David S. Hong
Rossana Berardi
Alexander Krohn
Yong Zhang
Source :: Journal of Thoracic Oncology. 11:S257-S258
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: 0301 basic medicine
Pulmonary and Respiratory Medicine
Oncology
medicine.medical_specialty
Capmatinib
business.industry
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
medicine
In patient
Intensive care medicine
business

Full Text Access

Tools